Trimel Pharmaceuticals Corp. (OTCMKTS:TRLPF) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Saturday.
Trimel Pharmaceuticals Corp. (OTCMKTS TRLPF) opened at 0.0934 on Friday. Trimel Pharmaceuticals Corp. has a 52-week low of $0.07 and a 52-week high of $0.20. The company has a 50 day moving average price of $0.09 and a 200-day moving average price of $0.09. The firm has a market cap of $19.91 million, a price-to-earnings ratio of 9.3400 and a beta of 1.38.
Trimel Pharmaceuticals Corp. Company Profile
Trimel Pharmaceuticals Corporation is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men’s health, women’s health and respiratory medicine. The Corporation holds a license for the development and marketing rights to certain products utilizing a nasal gel drug delivery technology platform and owns a novel unit-dose dry power inhaler / nasal dispersion system.
What are top analysts saying about Trimel Pharmaceuticals Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Trimel Pharmaceuticals Corp. and related companies.